Contrasting Pathfinder Cell Therapy (OTCMKTS:PFND) & Celcuity (NASDAQ:CELC)

Celcuity (NASDAQ:CELC) and Pathfinder Cell Therapy (OTCMKTS:PFND) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Risk & Volatility

Celcuity has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Pathfinder Cell Therapy has a beta of -4.82, meaning that its share price is 582% less volatile than the S&P 500.

Profitability

This table compares Celcuity and Pathfinder Cell Therapy’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-179.00%	-57.97%
Pathfinder Cell Therapy	N/A	N/A	N/A

Insider and Institutional Ownership

63.3% of Celcuity shares are held by institutional investors. 15.8% of Celcuity shares are held by company insiders. Comparatively, 15.1% of Pathfinder Cell Therapy shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Celcuity and Pathfinder Cell Therapy”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$111.78 million	($3.67)	-27.40
Pathfinder Cell Therapy	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Celcuity and Pathfinder Cell Therapy, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1	1	7	1	2.80
Pathfinder Cell Therapy	0	0	0	0	0.00

Celcuity currently has a consensus target price of $105.25, suggesting a potential upside of 4.67%. Given Celcuity’s stronger consensus rating and higher probable upside, analysts plainly believe Celcuity is more favorable than Pathfinder Cell Therapy.

Summary

Celcuity beats Pathfinder Cell Therapy on 7 of the 9 factors compared between the two stocks.

About Celcuity

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.